NCT07490262 2026-04-16A Study to Evaluate the Efficacy and Safety of IBI310 and Sintilimab Combination Therapy in Patients With Hepatocellular Carcinoma as First-line Treatment.Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.Phase 2/3 Recruiting680 enrolled